Terms: = Brain cancer AND SMARCA4, hSNF2b, 6597, P51532, BRG1, SNF2L4, SNF2, SWI2, FLJ39786, BAF190, SNF2LB, SNF2-BETA, ENSG00000127616
95 results:
1. [Cytopathological characteristics of smarca4-deficient thoracic undifferentiated tumors in serous effusion].
Wang WN; Liu XT; Liang YM
Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):143-148. PubMed ID: 38281781
[No Abstract] [Full Text] [Related]
2. Clinical and Genomic Predictors of Adverse Events in Newly Diagnosed Glioblastoma.
Lim-Fat MJ; Iorgulescu JB; Rahman R; Bhave V; Muzikansky A; Woodward E; Whorral S; Allen M; Touat M; Li X; Xy G; Patel J; Gerstner ER; Kalpathy-Cramer J; Youssef G; Chukwueke U; McFaline-Figueroa JR; Nayak L; Lee EQ; Reardon DA; Beroukhim R; Huang RY; Bi WL; Ligon KL; Wen PY
Clin Cancer Res; 2024 Apr; 30(7):1327-1337. PubMed ID: 38252427
[TBL] [Abstract] [Full Text] [Related]
3. Characterization of a Preclinical In Vitro Model Derived from a smarca4-Mutated Sinonasal Teratocarcinosarcoma.
Lorenzo-Guerra SL; Codina-Martínez H; Suárez-Fernández L; Cabal VN; García-Marín R; Riobello C; Vivanco B; Blanco-Lorenzo V; Sánchez-Fernández P; López F; Llorente JL; Hermsen MA
Cells; 2023 Dec; 13(1):. PubMed ID: 38201285
[TBL] [Abstract] [Full Text] [Related]
4. Dedifferentiated and Undifferentiated Ovarian Carcinoma: An Aggressive and Molecularly Distinct Ovarian Tumor Characterized by Frequent SWI/SNF Complex Inactivation.
Tessier-Cloutier B; Kommoss FKF; Kolin DL; Němejcová K; Smith D; Pors J; Stewart CJR; McCluggage WG; Foulkes WD; von Deimling A; Köbel M; Lee CH
Mod Pathol; 2024 Jan; 37(1):100374. PubMed ID: 37925057
[TBL] [Abstract] [Full Text] [Related]
5. MYC overexpression and smarca4 loss cooperate to drive medulloblastoma formation in mice.
Göbel C; Godbole S; Schoof M; Holdhof D; Kresbach C; Loose C; Neumann J; Schüller U
Acta Neuropathol Commun; 2023 Nov; 11(1):174. PubMed ID: 37919824
[TBL] [Abstract] [Full Text] [Related]
6. Comparative Analysis of the Embryonal brain Tumors Based on Their Molecular Features.
Shcherbina V; Kovalevska L; Pedachenko E; Malysheva T; Kashuba E
Discov Med; 2023 Oct; 35(178):733-749. PubMed ID: 37811612
[TBL] [Abstract] [Full Text] [Related]
7. Next-generation bromodomain inhibitors of the SWI/SNF complex enhance DNA damage and cell death in glioblastoma.
Yang C; He Y; Wang Y; McKinnon PJ; Shahani V; Miller DD; Pfeffer LM
J Cell Mol Med; 2023 Sep; 27(18):2770-2781. PubMed ID: 37593885
[TBL] [Abstract] [Full Text] [Related]
8. Establishment and validation of preclinical models of smarca4-inactivated and ARID1A/ARID1B co-inactivated dedifferentiated endometrial carcinoma.
Wong NKY; Llaurado Fernandez M; Kommoss FKF; Praveen Kumar P; Kim H; Liu J; Zhang G; Coatham M; Lin YY; Haegert AM; Volik S; Le Bihan S; Collins CC; Fu Y; Postovit LM; von Deimling A; Wu R; Xue H; Wang Y; Köbel M; Carey MS; Lee CH
Gynecol Oncol; 2023 Sep; 176():162-172. PubMed ID: 37556934
[TBL] [Abstract] [Full Text] [Related]
9. brain and Spinal Cord Tumors of Embryonic Origin.
Lampros M; Alexiou GA
Adv Exp Med Biol; 2023; 1405():405-420. PubMed ID: 37452947
[TBL] [Abstract] [Full Text] [Related]
10. Recurrent atypical teratoid/rhabdoid tumors (AT/RT) reveal discrete features of progression on histology, epigenetics, copy number profiling, and transcriptomics.
Johann PD; Altendorf L; Efremova EM; Holsten T; Steinbügl M; Nemes K; Eckhardt A; Kresbach C; Bockmayr M; Koch A; Haberler C; Antonelli M; DeSisto J; Schuhmann MU; Hauser P; Siebert R; Bens S; Kool M; Green AL; Hasselblatt M; Frühwald MC; Schüller U
Acta Neuropathol; 2023 Sep; 146(3):527-541. PubMed ID: 37450044
[TBL] [Abstract] [Full Text] [Related]
11. The role of chromatin remodeler smarca4/brg1 in brain cancers: a potential therapeutic target.
Navickas SM; Giles KA; Brettingham-Moore KH; Taberlay PC
Oncogene; 2023 Jul; 42(31):2363-2373. PubMed ID: 37433987
[TBL] [Abstract] [Full Text] [Related]
12. Concurrent high-grade glioma with cavernous malformations and pathogenic variants in PDCD10 and smarca4.
Glanz H; Damodharan SN; Smith-Simmer K; Helgager J; Puccetti D
Childs Nerv Syst; 2023 Nov; 39(11):3311-3315. PubMed ID: 37328659
[TBL] [Abstract] [Full Text] [Related]
13. Tazemetostat for tumors harboring SMARCB1/smarca4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C.
Chi SN; Yi JS; Williams PM; Roy-Chowdhuri S; Patton DR; Coffey BD; Reid JM; Piao J; Saguilig L; Alonzo TA; Berg SL; Ramirez NC; Jaju A; Mhlanga JC; Fox E; Hawkins DS; Mooney MM; Takebe N; Tricoli JV; Janeway KA; Seibel NL; Parsons DW
J Natl Cancer Inst; 2023 Nov; 115(11):1355-1363. PubMed ID: 37228094
[TBL] [Abstract] [Full Text] [Related]
14. Facial analytics based on a coordinate extrapolation system (zFACE) for morphometric phenotyping of developing zebrafish.
Maili L; Ruiz OE; Kahan PH; Chiu F; Larson ST; Hashmi SS; Hecht JT; Eisenhoffer GT
Dis Model Mech; 2023 Jun; 16(6):. PubMed ID: 37102214
[TBL] [Abstract] [Full Text] [Related]
15. Targeting SWI/SNF ATPases in H3.3K27M diffuse intrinsic pontine gliomas.
Mota M; Sweha SR; Pun M; Natarajan SK; Ding Y; Chung C; Hawes D; Yang F; Judkins AR; Samajdar S; Cao X; Xiao L; Parolia A; Chinnaiyan AM; Venneti S
Proc Natl Acad Sci U S A; 2023 May; 120(18):e2221175120. PubMed ID: 37094128
[TBL] [Abstract] [Full Text] [Related]
16. Characterization of Switch/Sucrose Nonfermenting Complex Proteins and Nestin Expression in a Cohort of Pediatric Central Nervous System Tumors.
Wang XQ; Tessier-Cloutier B; Saunders J; Harvey M; Armstrong L; Ng T; Dunham C; Bush JW
Appl Immunohistochem Mol Morphol; 2023 May-Jun 01; 31(5):304-310. PubMed ID: 37036408
[TBL] [Abstract] [Full Text] [Related]
17. Atypical teratoid/rhabdoid tumoroids reveal subgroup-specific drug vulnerabilities.
Paassen I; Williams J; Ríos Arceo C; Ringnalda F; Mercer KS; Buhl JL; Moreno N; Federico A; Franke NE; Kranendonk M; Upadhyaya SA; Kerl K; van de Wetering M; Clevers H; Kool M; Hoving EW; Roussel MF; Drost J
Oncogene; 2023 May; 42(20):1661-1671. PubMed ID: 37020038
[TBL] [Abstract] [Full Text] [Related]
18. Chromatin remodeler Activity-Dependent Neuroprotective Protein (ADNP) contributes to syndromic autism.
D'Incal CP; Van Rossem KE; De Man K; Konings A; Van Dijck A; Rizzuti L; Vitriolo A; Testa G; Gozes I; Vanden Berghe W; Kooy RF
Clin Epigenetics; 2023 Mar; 15(1):45. PubMed ID: 36945042
[TBL] [Abstract] [Full Text] [Related]
19. Clinicopathological and molecular characterization of a case classified by DNA‑methylation profiling as "CNS embryonal tumor with BRD4-LEUTX fusion".
Lebrun L; Allard-Demoustiez S; Gilis N; Van Campenhout C; Rodesch M; Roman C; Calò P; Lolli V; David P; Fricx C; De Witte O; Escande F; Maurage CA; Salmon I
Acta Neuropathol Commun; 2023 Mar; 11(1):46. PubMed ID: 36934287
[TBL] [Abstract] [Full Text] [Related]
20. Characterization of Central Nervous System Clinico-Genomic Outcomes in ALK-Positive Non-Small Cell Lung cancer Patients with brain Metastases Treated with Alectinib.
Miao E; Eichholz JE; Lebow ES; Flynn J; Zhang Z; Walch H; Hubbeling H; Beal K; Moss NS; Yu KK; Meng A; Kelly DW; Gomez DR; Li BT; Rimner A; Schultz N; Drilon A; Imber BS; Pike LRG
Lung Cancer; 2023 Apr; 178():57-65. PubMed ID: 36780766
[TBL] [Abstract] [Full Text] [Related]
[Next]
